GLSI

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Greenwich Lifesciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Greenwich Lifesciences Inc. EPS for the last quarter amounts to -0.30 USD, increased 50.00 % YoY.

Greenwich Lifesciences Inc (GLSI) has 4 emplpoyees as of January 10 2026.

Today GLSI has the market capitalization of 350.24M USD.